M2 facility to keep Australia's medtech industry healthy
05 September, 2017CSIRO, Monash University and the Monash Health Translation Precinct (MHTP) have announced the creation of M2 — a new facility that combines technology, research and medical science.
Boehringer Ingelheim initiates Phase IIa study of liver disease drug
25 August, 2017Boehringer Ingelheim has initiated a European and North American Phase IIa trial in non-alcoholic steatohepatitis (NASH) of investigational drug candidate BI 1467335, acquired from fellow pharma company Pharmaxis in May 2015.
Adherium sells its 100,000th Smartinhaler
17 August, 2017Digital health company Adherium is celebrating a significant milestone, having recently manufactured and sold its 100,000th Smartinhaler.
Treating childhood allergies with gut bacteria
16 August, 2017 by Lauren DavisAustralian biotech company Ondek is on a mission to develop an immunotherapy based on the gram-negative bacterium Helicobacter pylori, which it hopes to eventually deploy as a new treatment for childhood allergy.
Bendable batteries can be implanted in the body
11 August, 2017Chinese researchers have engineered bendable batteries, suitable for implantation in the human body, which can run on body-inspired liquids such as a normal IV saline solution and a cell-culture medium.
New regenerative tissue technology developed
08 August, 2017Scientists have developed a new technology, tissue nano-transfection (TNT), that can generate any cell type of interest for treatment within a patient's own body.
Novogen says Cantrixil trial progressing as planned
08 August, 2017Novogen, an ASX-listed oncology drug development company, has announced that its phase I clinical trial of Cantrixil in ovarian cancer is progressing as planned.
VivaGel BV trials declared a success
08 August, 2017Starpharma has announced that its two phase 3 trials of VivaGel BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective, demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data.
Nanocapsules could create artificial organs, treat incurable diseases
27 July, 2017 by Adam FloranceResearchers have developed a significant advancement in manufacturing better-quality nanocapsules which may lead the way to new treatments for currently incurable diseases, including diabetes.
Aus start-up completes first-in-human trial of bone 'glue'
21 July, 2017Australian biotech company Trimph has successfully completed a first-in-human trial of its proprietary bone 'glue' — said to be the only bone graft substitute in the world to be applied in liquid form.
Stem cells show potential for asthma treatment
06 July, 2017Monash University scientists have published the results of their study into mesenchymal stem cells (MSCs) from Cynata Therapeutics, revealing that the company's technology holds promise as a treatment for chronic asthma.
Innate reveals "distressing" MS trial results
30 June, 2017Innate Immunotherapeutics has reluctantly announced that its MS therapy MIS416 showed no meaningful or statistically significant results in a recent Phase 2B trial, with the company's shares dropping a whopping 92% as a result.
Prima says IMP321 trial progressing well
29 June, 2017Prima BioMed has announced that the company's two active clinical trials in IMP321 are progressing well.
Canadian CRO selected to reformulate cancer inhibitor
27 June, 2017PharmAust has appointed contract research organisation BRI Pharmaceutical Research Inc to reformulate its lead drug candidate, Monepantel (MPL), for clinical trials.
Clinical trials provide $1.1bn to economy
22 June, 2017Clinical trials accounted for roughly $1.1 billion in gross expenditure in 2015, and the annual expenditure could reach 2 billion in the next 10 years.
